671 related articles for article (PubMed ID: 22491770)
41. [Morphologic manifestations of human papillomavirus infection in the vulvar and anogenital region].
Hadzić B; Djurdjević S; Hadzić M; Jerant-Patić V
Med Pregl; 1998; 51(5-6):265-70. PubMed ID: 9720356
[TBL] [Abstract][Full Text] [Related]
42. Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes.
Lo Cigno I; Calati F; Borgogna C; Zevini A; Albertini S; Martuscelli L; De Andrea M; Hiscott J; Landolfo S; Gariglio M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776268
[TBL] [Abstract][Full Text] [Related]
43. A humanized mouse model of HPV-associated pathology driven by E7 expression.
Buitrago-Pérez Á; Hachimi M; Dueñas M; Lloveras B; Santos A; Holguín A; Duarte B; Santiago JL; Akgül B; Rodríguez-Peralto JL; Storey A; Ribas C; Larcher F; del Rio M; Paramio JM; García-Escudero R
PLoS One; 2012; 7(7):e41743. PubMed ID: 22911850
[TBL] [Abstract][Full Text] [Related]
44. Potential Effects of Human Papillomavirus Type Substitution, Superinfection Exclusion and Latency on the Efficacy of the Current L1 Prophylactic Vaccines.
Hampson IN; Oliver AW; Hampson L
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374445
[TBL] [Abstract][Full Text] [Related]
45. The Human Papillomavirus E6 Oncoprotein Targets USP15 and TRIM25 To Suppress RIG-I-Mediated Innate Immune Signaling.
Chiang C; Pauli EK; Biryukov J; Feister KF; Meng M; White EA; Münger K; Howley PM; Meyers C; Gack MU
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263274
[TBL] [Abstract][Full Text] [Related]
46. Human papillomaviruses and the interferon response.
Beglin M; Melar-New M; Laimins L
J Interferon Cytokine Res; 2009 Sep; 29(9):629-35. PubMed ID: 19715460
[TBL] [Abstract][Full Text] [Related]
47. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
48. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
Stanley M; Gissmann L; Nardelli-Haefliger D
Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
[TBL] [Abstract][Full Text] [Related]
49. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
50. Immune evasion mechanisms of human papillomavirus: An update.
Steinbach A; Riemer AB
Int J Cancer; 2018 Jan; 142(2):224-229. PubMed ID: 28865151
[TBL] [Abstract][Full Text] [Related]
51. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
52. Pathology and epidemiology of HPV infection in females.
Stanley M
Gynecol Oncol; 2010 May; 117(2 Suppl):S5-10. PubMed ID: 20304221
[TBL] [Abstract][Full Text] [Related]
53. Spectrum of genital human papillomavirus infection in a female adolescent population.
Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
[TBL] [Abstract][Full Text] [Related]
54. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
[TBL] [Abstract][Full Text] [Related]
55. HPV modulation of host immune responses.
Feller L; Wood NH; Khammissa RA; Chikte UM; Meyerov R; Lemmer J
SADJ; 2010 Jul; 65(6):266-8. PubMed ID: 20879650
[TBL] [Abstract][Full Text] [Related]
56. Human papillomavirus vaccines: a warty problem.
Galloway DA
Infect Agents Dis; 1994 Aug; 3(4):187-93. PubMed ID: 7827787
[TBL] [Abstract][Full Text] [Related]
57. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia.
Egawa N; Egawa K; Griffin H; Doorbar J
Viruses; 2015 Jul; 7(7):3863-90. PubMed ID: 26193301
[TBL] [Abstract][Full Text] [Related]
58. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768
[TBL] [Abstract][Full Text] [Related]
59. Human papillomavirus infection, cancer & therapy.
Grm HS; Bergant M; Banks L
Indian J Med Res; 2009 Sep; 130(3):277-85. PubMed ID: 19901437
[TBL] [Abstract][Full Text] [Related]
60. Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.
Scagnolari C; Cannella F; Pierangeli A; Mellinger Pilgrim R; Antonelli G; Rowley D; Wong M; Best S; Xing D; Roden RBS; Viscidi R
J Virol; 2020 Jun; 94(12):. PubMed ID: 32295905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
